Customer Letters

Please note: The following Customer Letters, do not replace the version that you receive from your local Canadian Blood Services site.

* The contents of the customer letters available on this site are current as of their dates of publication. If required, contact your local Hospital Liaison Specialist to determine if the letter is still current. 

Category
done
done
done
Displaying 151 - 200 of 370
Date Sort ascending
CL_2021-29.pdf

INFORMATION ONLY
Fibrinogen concentrate – no restrictions on brand mix

Customer Letter 2021-29 (PDF)

CL_2021-28.pdf

ACTION REQUIRED
Introducing pathogen-reduced Pooled Platelets and associated new ISBT Component Codes
Ottawa site served hospitals only

Customer Letter 2021-28 (PDF)

CL_2021-27.pdf

ACTION REQUIRED
Recall Notification Distribution

Customer Letter 2021-27 (PDF) | NCRW Example (JPG)

CL_2021-26.pdf

ACTION REQUIRED
Introduction of ACD-A Apheresis Frozen Plasma

Customer Letter 2021-26 (PDF)

CL_2021-25.pdf

INFORMATION ONLY
Hizentra® 20% Liquid 20 mL (4g) Pre-filled Syringe Availability

Customer Letter 2021-25 (PDF) | Hizentra® Prefilled Syringe (PDF) | Hizentra® Fact Sheet (PDF)

CL_2021-24.pdf

INFORMATION ONLY
Special Request Order Form

Customer Letter 2021-24 (PDF)

CL_2021-23.pdf

INFORMATION ONLY
Albumin 5% 500 mL Availability

Customer Letter 2021-23 (PDF) | Albumin 5% Introduction Letter (PDF) | Product Profile Albumin (PDF)

CL_2021-22.pdf

INFORMATION ONLY
Bacterial Test Result Notification to Hospitals – New Form

Customer Letter 2021-22 (PDF) | Bacterial Testing Results Notification (PDF)

CL_2021-21.pdf

INFORMATION ONLY
Introduction of Fibryga® Kit - Now Co-Packaged with Water for Injection

Customer Letter 2021-21 (PDF) | Fibryga Kit with WFI CBS HCP Customer Letter (PDF)

CL_2021-20.pdf

INFORMATION ONLY
Updated Share Splits for Intravenous Immunoglobulins

Customer Letter 2021-20 (PDF)

CL_2021-19.pdf

INFORMATION ONLY
RiaSTAP® Reconstitution Devices “Spike and Syringe Filter” available in RiaSTAP® package

Customer Letter 2021-19 (PDF) | RiaSTAP® Reconstitution Devices “Spike and Syringe Filter” now available in RiaSTAP® package (PDF)

CL_2021-18.pdf

INFORMATION ONLY
Introduction of HAEGARDA®

Customer Letter 2021-18 (PDF) | Product Profile Template HAEGARDA® (PDF) | HAEGARDA vendor letter (PDF)

CL_2021-17.pdf

INFORMATION ONLY
Intravenous Immunoglobulin (IVIg) Brand Switching Guidance and Resources from The National Advisory Committee on Blood and Blood Products (NAC)

Customer Letter 2021-17 (PDF) | Intravenous Immunoglobulin (IVIg) Brand Switching (PDF)

CL_2021-16.pdf

INFORMATION ONLY
Follow-up of Canadian Blood Services Platelet Bacterial Testing Results

Customer Letter 2021-16 (PDF) | Follow-up of Canadian Blood Services Platelet Bacterial Testing Results (PDF)

CL_2021-15.pdf

INFORMATION ONLY
Updates regarding Hemlibra® (emicizumab injection)

Customer Letter 2021-15 (PDF) | Drug Product Shelf Life Reduction (PDF) | Introduction of Transfer Needle with Filter (PDF)

CL_2021-14.pdf

INFORMATION ONLY
Octagam® 10% Availability

Customer Letter 2021-14 (PDF) | Product Profile Octagam (PDF) | Octagam Availability Customer Letter (PDF)

CL_2021-13.pdf

INFORMATION ONLY
New CSL Behring Contact Number for Urgent Inquiries and Afterhours Service

Customer Letter 2021-13 (PDF) | CSL Behring Contact Number (PDF)

CL 2021-12.pdf

INFORMATION ONLY
WinRho® SDF Labelling – Repackaged WinRho® SDF 1000 mcg (5000 IU) Lot 230029571

Customer Letter 2021-12 (PDF) | Customer notification repackaging activity for WinRho® (PDF)

CL_2021-11.pdf

INFORMATION ONLY
Updates to Solvent Detergent Plasma - Request Form

Customer Letter 2021-11 (PDF) | Solvent Detergent Plasma - Request Form

CL 2021-09.pdf

INFORMATION ONLY
Introduction of X-ray Irradiation

Customer Letter 2021-09 (PDF) 

CL 2021-10.pdf

ACTION REQUIRED
Hospital Monitoring of Ig Supply

Customer Letter 2021-10 (PDF) 

CL_2021-08.pdf

ACTION REQUIRED
Immunoglobulin (Ig) Inventory Update and Reminder of Action for Hospitals

Customer Letter 2021-08 (PDF) | National Emergency Blood Management Committee Letter (PDF)

CL_2021-07.pdf

INFORMATION ONLY
Updates to the Blood Component and Special Request Order Forms

Customer Letter 2021-07 (PDF) | Blood Component Order Form (PDF) | Special Request Order Form (PDF)

CL_2021-06.pdf

INFORMATION ONLY
Update to J82 and E38 Shipping Containers for Inter-Hospital Transfers

Customer Letter 2021-06 (PDF)

CL_2021-05.pdf

INFORMATION ONLY
Release of Revised Circular of Information for Red Blood Cells, Platelets, and Plasma

Customer Letter 2021-05 (PDF)

CL_2021-04.pdf

INFORMATION ONLY
WinRho® SDF Labelling

Customer Letter 2021-04 (PDF) | Saol Customer Notification

CL_2021-03.pdf

INFORMATION ONLY
Privigen® Inventory

Customer Letter 2021-03 (PDF)

CL_2021-02.pdf

INFORMATION ONLY
Update on Panhematin® Packing Supply

Customer Letter 2021-02 (PDF)

CL_2021-01.pdf

INFORMATION ONLY
Revision to Transfusion Related Acute Lung Injury (TRALI) Patient Data Form

Customer Letter 2021-01 (PDF)

CL_2020-51.pdf

INFORMATION ONLY
2020 Holiday Message and Inventory Update

Customer Letter 2020-51 (PDF)

CL_2020-50.pdf

ACTION REQUIRED
Upcoming Changes to Ig Supply and Actions for Hospitals

Customer Letter 2020-50 (PDF)

CL_2020-49.pdf

INFORMATION ONLY
Changes to Labelling on Back of Plasma Components

Customer Letter 2020-49 (PDF)

CL_2020-48.pdf

INFORMATION ONLY
RiaSTAP® Reconstitution Devices “Spike and Syringe Filter" now available through Bayshore

Customer Letter 2020-48 (PDF) | RiaSTAP Syringe Filter (PDF)

CL_2020-47.pdf

INFORMATION ONLY
Notice of Completion- eProgesa Upgrades

Customer Letter 2020-47 (PDF)

CL_2020-46.pdf

INFORMATION ONLY
Changes to Apheresis Platelet Yield Testing

Customer Letter 2020-46 (PDF)

CL_2020-45.pdf

ACTION REQUIRED
Notice of eProgesaOutage Nov 1-2, 2020 - Product and Service Impacts

Customer Letter 2020-45 (PDF)

CL_2020-44.pdf

ACTION REQUIRED
Immunoglobulin (Ig) Inventory Update and Action for Hospitals

Customer Letter 2020-44 (PDF) | NEBMC Letter (PDF)

CL_2020-43.pdf

INFORMATION ONLY
Fibryga® Product Monograph Changes

Customer Letter 2020-43 (PDF) | Fibryga® Product Monograph changes (PDF)

CL_2020-42.pdf

INFORMATION ONLY
Compatibility Testing Interference Risk in Patients Being Treated with Sarclisa™ (Isatuximab)

Customer Letter 2020-42 (PDF) | CBS Letter Isatuximab (PDF)

CL_2020-41.pdf

INFORMATION ONLY
Adynovate® 3000 IU Available

Customer Letter 2020-41 (PDF) | 3000 IU Adynovate Customer Letter (PDF)

CL_2020-40.pdf

INFORMATION ONLY
Improving Red Blood Cell Utilization

Customer Letter 2020-40 (PDF)

CL_2020-39.pdf

INFORMATION ONLY
Electronic Fillable Patient Requisition Forms

Customer Letter 2020-39 (PDF)

CL_2020-38.pdf

INFORMATION ONLY
Obizur® Temporary Labelling Update

Customer Letter 2020-38 (PDF) | Customer Letter Obizur

CL_2020-37.pdf

ACTION REQUIRED
FEIBA 2500IU Shortage

Customer Letter 2020-37 (PDF)

CL_2020-36.pdf

INFORMATION ONLY
Plasma Protein and Related Products Contract Extensions

Customer Letter 2020-36 (PDF)

CL_2020-35.pdf

INFORMATION ONLY
Panzyga 10g Available

Customer Letter 2020-35 (PDF)

CL_2020-34.pdf

INFORMATION ONLY
Privigen® 10g and 40g Sizes Available

Customer Letter 2020-34 (PDF)

CL_2020-33.pdf

ACTION REQUIRED
Cutaquig®4g Inventory

Customer Letter 2020-33 (PDF)

CL_2020-31.pdf

INFORMATION ONLY
Octaplasma™ Blood Group B

Customer Letter 2020-31 (PDF)

CL_2020-32.pdf

INFORMATION ONLY
Takeda Canada Inc.Amalgamation Notification

Customer Letter 2020-32 (PDF) | CBS - Takeda Amalgamation